Amit Bansal
Mercer University, USA
Title: Bio-fabrication and evaluation of alginate chitosan microcapsules of Insulin secreting β TC-6 cells in the treatment of Type 1 diabetes mellitus
Biography
Biography: Amit Bansal
Abstract
Type 1 diabetes mellitus (T1DM) is a disease, characterized by lack of pancreatic islet function. Whole tissue transplantation appears to be viable alternative in the management of T1DM due to limitation of exogenous insulin therapy. Th is study aims at fabrication and evaluation of alginate-chitosan microcapsule encapsulated insulin secreting β TC-6 cells using specialized spraying
nozzle. Microcapsules encapsulated with β TC-6 cells were fabricated using novel spraying device producing uniform spherical microcapsules. Microcapsules were characterized for permeability using molecular weight markers, stability, and cell viability using live dead staining kit. Microencapsulated β TC-6 cells were transplanted intra-peritoneally in streptozotocin (STZ) induced diabetic mice and monitored for decrease in blood glucose level and immune acceptance. Spherical microcapsules with diameter in the range of 250-350 μm were prepared at an air fl ow rate of 250 L/hr. Microencapsulated β TC-6 cells in alginate capsules demonstrated prolonged viability. Mice in microencapsulated cells group received microencapsulated β TC-6 cells maintains normoglycemia for 35±5 days before rejection. However, mice in unencapsulated cells group received naked β TC-6 cells rejected graft within 1 or 2 days and exhibit both cellular and humoral immune responses. CD4 T-cells mediated Th 2 response i.e. humoral response was predominant in microencapsulated β TC-6 cells group and that was further confi rmed from elevated levels of CD45R. Microcapsules produced by specialized nozzle were reproducible with narrow size distribution and in addition provides fl exibility in producing diff erent sized capsules. Our fi ndings for in-vivo study revealed that transplantation of microencapsulated β TC-6 cells may be a viable
alternative in the management of T1DM with greater immune acceptance.